51 results about "Septic shock" patented technology

The present invention relates to a D-galactopyranose compound of formula (1)whereinthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and / or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

本发明实施例公开了一种基于蛋白质组学的脓毒症休克患者液体管理策略预测方法。所述方法包括：收集脓毒症休克患者的血浆样本，检测蛋白质标志物的表达水平，所述蛋白质标志物为GAL、NFASC、MICB_MICA、MAP2K6、JCHAIN和CSF3的组合；基于亚组识别模型计算效益得分，获得脓毒症休克患者的液体管理策略结果。本发明通过收集脓毒症休克患者的临床数据和蛋白质表达数据，采用LASSO回归分析，构建基于上述蛋白质标志物的亚组识别模型，进而获得效益评分，基于效益评分能预测患者液体管理策略方案的适用性，为脓毒症休克患者的液体治疗提供了可靠的方案，实现个体化和精准的液体治疗，在临床具有较好的应用前景。

The present invention provides a therapeutic agent for sepsis and / or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and / or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

Uses of novel peptide analogs of a θ-defensin that have been developed which provide a biphasic effect in treating infection and / or sepsis are described. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensin.

The invention relates to the technical field of medicines, in particular to application of AV-412. The invention relates to an application of AV-412 in preparation of an NLRP3 inflammasome inhibitor. The invention discloses application of AV-412 in preparation of a medicine for treating infectious shock. The invention discloses application of AV-412 in preparation of a medicine for treating acute liver injury. The invention discloses application of AV-412 in preparation of a medicine for treating acute peritonitis. The invention provides a new choice for medicines for preventing or treating NLRP3 inflammasome related diseases, and also provides a new medicine with treatment potential for infectious shock, acute liver injury and acute peritonitis.

The invention relates to the technical field of medicines, in particular to application of garcinia cambogia ketone C. The invention relates to an application of gamboge C in preparation of an NLRP3 inflammasome inhibitor. The invention relates to an application of garcinia cambogia ketone C in preparation of a medicine for treating infectious shock. The invention relates to an application of garcinia flavone C in preparation of a medicine for treating acute liver injury. The invention relates to an application of garcinia flavone C in preparation of a medicine for treating acute peritonitis. The invention provides a new choice for medicines for preventing or treating NLRP3 inflammasome related diseases, and also provides a new medicine with treatment potential for infectious shock, acute liver injury and acute peritonitis.

Methods of using lipid binding protein molecules to treat a subject having or at risk of one or more conditions, such as sepsis (e.g., septic shock).

The application provides a blood stream infection related septic shock multi-modal fusion prediction method and system, belonging to the field of intelligent medical treatment, and solving the problems of long time consumption, insufficient sensitivity and insufficient multi-modal information analysis capability in blood stream infection related septic shock. The method comprises: acquiring multi-modal clinical data of a target patient suspected of blood stream infection within a preset observation time window to obtain a multi-modal multi-scale feature sequence formed by combining each modality spatiotemporal feature vector sequence; inputting the multi-modal multi-scale feature sequence into a time sequence encoding network based on a multi-head attention mechanism to obtain an aligned multi-modal time sequence representation sequence; setting a learnable modality weight parameter for each modality, and updating the learnable modality weight parameter, the encoder and the time sequence encoding network through a task loss function according to the label of whether blood stream infection related septic shock occurs or not in the training process to obtain a multi-modal fusion model for prediction.

The present application provides a kind of fused ring compound and its preparation and use. Specifically, the structure of the compound is as shown in formula (I), the compound of formula (I) or its pharmaceutically acceptable salt, for increasing the activity of liver-type phosphofructokinase, can be used for treating diseases related to liver-type phosphofructokinase activity, such as cancer, diabetes, sepsis and septic shock.I.

The invention relates to an early warning method for infectious shock and a storage medium. Firstly, the limitation of a single mode is broken through by obtaining multi-mode physiological feature parameters of a user; then, constructing a graph neural network according to the multi-modal physiological feature parameters to obtain spatial correlation features, and obtaining time evolution features based on short-term time sequence features and long-term time sequence features; the method comprises the following steps of: obtaining a time-space feature vector by fusing a space correlation feature and a time evolution feature, outputting a risk probability and a time sensitivity index of the infectious shock of a user through a two-channel mechanism, and predicting the risk of the infectious shock from two dimensions of time and space, so that the risk level of the user can be more accurately predicted, and the risk prediction accuracy is improved. And the timeliness of risk early warning is improved, and timely intervention on the infectious shock of the user is realized, so that the treatment effect is improved.

Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and / or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis; Crohn's disease; J-pouch; fistulising Crohn's disease; a Colitis which can be microscopic, lymphocytic or collagenous; an eosinophilic colitis; indeterminate colitis; idiopathic colitis; diverticulosis and diverticulitis; relapsing diverticulitis; constipation associated inflammatory bowel disease and / or small intestinal bacterial overgrowth; Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS; periodontitis; rheumatoid arthritis; respiratory infections, appendicitis, vascular disorders such as thrombophlebitis; bacteremia; osteomyelitis; septic shock; Alzheimer's disease; Lemierre syndrome (postanginal sepsis); colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis); pharyngitis; otitis; sinusitis; and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.

This invention relates to the field of biomedical technology and proposes the use of TM9SF1 in the preparation of a reagent for monitoring the course of sepsis. Specifically, it proposes the use of a marker in the preparation of a reagent for monitoring the course of sepsis, wherein the marker comprises the TM9SF1 gene or the mRNA corresponding to the TM9SF1 gene. In the technical solution of this invention, a nomogram model for predicting the severity of sepsis can be constructed by using the TM9SF1 gene as a marker. Receiver-operating characteristic (ROC) curve validation demonstrated an AUC of 0.883, a sensitivity of 91.5%, and a specificity of 78.4%. For predicting mortality in patients with septic shock, the nomogram model achieved a C-index of 0.931.

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. In particular the invention provides dosages and formulation for low anticoagulant heparin in the treatment of sepsis or septic shock. The invention further provides compositions for use in reducing C-reactive protein (CRP) levels in a patient, for example in the treatment, prevention or amelioration of disease where CRP plays a role, such as sepsis.

To provide a mixture for use in the treatment of hypotension in a human subject having sepsis.SOLUTION: The mixture comprises: (a) a first empty liposome comprising cholesterol, wherein an amount of cholesterol is 45% to 55% (weight per weight) and the liposome does not incorporate a pharmaceutical drug; and (b) a second empty liposome comprising sphingomyelin, wherein the liposome does not incorporate a pharmaceutical drug. The mixture is administered to the human subject in at least two doses, including a first dose and a second dose, with an interval of 6 to 96 hours between the first dose and the second dose.SELECTED DRAWING: None

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

1. Name of the Design Product: Graphic User Interface for Diagnosis and Treatment Quality Control of Electronic Devices. 2. Use of the Design Product: For an electronic device. 3. Design Key Points of the Design Product: Lies in the graphic user interface. 4. Picture or Photograph that Best Illustrates the Design Key Points: Variant State Diagram 1. 5. Use of the Graphic User Interface: For diagnosis and treatment quality control of the management of septic shock bundle therapy. 6. Explanation of the Variant States of the Graphic User Interface: Click on "Diagnosis and Treatment" in the main view to enter Variant State Diagram 1; click on "qSOFA Score" or "Infection Confirmation" in the pop-up box in Variant State Diagram 1 to enter Variant State Diagram 2; click on "AI Evaluation qSOFA >= 2 Points" in the middle of the interface in Variant State Diagram 2 to enter Variant State Diagram 3; click on "Systolic Blood Pressure <= 100 mmHg" on the left side in Variant State Diagram 3 to enter Variant State Diagram 4. 7. Other Circumstances Requiring Explanation: Other Explanation: X is the text content; the coated content is the content screen.

The present invention discloses a method for recommending the diagnosis and treatment of septic shock based on a knowledge graph. The method comprises the following steps: S1: defining relevant information in a knowledge graph for septic shock; S2: introducing symmetric, inverse, and combined relationships, and using the RotatE model to represent the knowledge graph; S3: using word2vec and the RotatE model to recommend treatment methods based on patient symptoms. The present invention constructs a knowledge graph based on five entities and seven relationships, introduces symmetric, inverse, and combined relationships, and uses the RotatE model to represent the knowledge graph for septic shock. Considering that some patient symptoms that may be queried in reality do not exist in the knowledge graph, the word2vec model is retrained to recommend treatment methods for symptoms that are not in the knowledge graph, assisting doctors in making clinical diagnosis and treatment decisions to achieve the best treatment results.

The invention belongs to the technical field of medicines, and particularly relates to a microneedle patch for disguising a macrophage cell membrane and a preparation method of the microneedle patch. Degradable high polymer material nano-particles camouflaged by the macrophage membrane are embedded in a microneedle array of the microneedle patch camouflaged by the macrophage membrane, and the degradable high polymer material nano-particles camouflaged by the macrophage membrane are wrapped with gambogic acid and oleic acid functionalized cerium dioxide nano-particles. Nanoparticles of the microneedle patch jointly load gambogic acid and oleic acid functionalized cerium dioxide, through microneedle transdermal drug delivery, active targeting of the drug to the liver is achieved by using natural inflammatory taxis of a macrophage membrane, the anti-inflammatory effect of gambogic acid and the anti-oxidation effect of cerium dioxide are synergistically exerted, polarization of macrophages is adjusted, and the anti-inflammatory effect of the drug on the liver is achieved. Therefore, the liver injury caused by the septic shock is treated.

This invention relates to the field of medical artificial intelligence technology and discloses a method for predicting the resuscitation status of patients with septic shock. The method includes: acquiring state parameters of the patient with septic shock; preprocessing the acquired state parameters to obtain input parameters; obtaining training data based on a critical care database; training a prediction model using the training data; inputting the input parameters into the trained prediction model to obtain a first prediction probability; and performing binary classification on the first prediction probability to obtain a final prediction result. The state parameters include target parameters, which include multiple variables such as mean arterial pressure, arterial blood lactate, base excess, pH, bicarbonate, and anion gap. This method and system for predicting the resuscitation status of patients with septic shock can prospectively output the overall probability of achieving resuscitation targets at the 6th hour using conventionally available multidimensional clinical information within 0-2 hours after admission to the ICU.

The invention relates to novel heteroaryl compounds of Formula (I), and pharmaceutically acceptable salts thereof; and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.

The invention discloses a model for predicting septic shock and death of a sepsis patient, which is characterized in that the model for predicting septic shock and death is composed of a septic shock prediction model and a sepsis patient death prediction model, and the establishment of the septic shock prediction model comprises the following steps: step 1, establishing a model for predicting septic shock and death of the sepsis patient; by means of multi-factor ridge regression analysis, HCT (hematocrit), SOFA score (sequential organ failure assessment), LAC (lactic acid) and claudin-5 are screened out to serve as independent risk factors of septic shock. According to the method, the septic shock prediction model and the sepsis patient death prediction model are combined and applied to clinical practice, the profound beneficial effects can be achieved, a comprehensive and systematic risk assessment tool is provided for clinicians through the combination, the clinicians can more accurately judge the shock and death risks of the sepsis patient, and the risk assessment accuracy is improved. Therefore, a more personalized and scientific treatment scheme can be formulated.

The invention relates to a method for the prediction of an increase of dipeptidyl peptidase 3 (DPP3) in a critically ill patient. In particular, the method comprises providing a sample from said patient, determining a level of Dipeptidyl peptidase 3 (DPP3) in said sample, comparing said level to a pre-determined threshold, wherein the level of DPP3 in said sample is indicative of an increase of DPP3 if said level of DPP3 is above a pre-determined threshold level, which is in the range between 22 and 40 ng / ml. Furthermore, the invention also relates to a method for the prevention of a DPP3 increase in a critical ill patient, wherein a DPP3 inhibitor is administered to the patient if the level of DPP3 is above a threshold between 40 ng / ml and 22 ng / ml and said DPP3 inhibitor is an anti-DPP3-antibody and / or and anti-DPP3-antibody fragment and / or anti-DPP3 scaffold. Moreover, the invention also relates to a DPP3 inhibitor for use in the prevention of a DPP3 increase in a critical ill patient.

Use of anisodamine hydrobromide in the preparation of a drug for treating sepsis and / or septic shock. Anisodamine hydrobromide can ameliorate CLP-induced changes in vital signs of rats, improve the morphology of lung tissue, regulate related target proteins, and produce a good therapeutic effect on sepsis and / or septic shock.

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

he disclosure relates generally to the field of sepsis. The disclosure also relates to anti-PAL antibodies, and to methods of using these anti-PAL antibodies to treat sepsis or septic shock. Methods for treating certain immunosuppressed states associated with recovery from sepsis using the anti-PAL antibodies are also disclosed.

The present invention relates to the diagnosis of sepsis and / or septic shock and monitoring the extent thereof; the early assessment of the risk of developing sepsis and / or septic shock; the prediction or determination or monitoring of the need for a therapy or intervention in a subject. The present invention relates to a method which comprises determining the level of a biomarker selected from the group consisting of ADM-Gly, PAMP, MR-proADM and CT-proADM or a fragment of at least five amino acids thereof, or the total ADM, or the ratio of the level of said biomarker to the level of ADM-Nffz, in a sample of a subject, and wherein the level of said biomarker or said ratio is indicative of sepsis and / or septic shock or the extent of sepsis and / or septic shock, or is predictive of an increased risk of developing sepsis and / or septic shock, or is indicative of the need for a therapy or intervention in said subject for sepsis and / or septic shock.